Use of rotational thromboelastometry for a global screening of coagulation profile in patients of myeloproliferative neoplasms.

Use of rotational thromboelastometry for a global screening of coagulation profile in patients of myeloproliferative neoplasms. Platelets. 2020 Apr 03;:1-4 Authors: Şahin DG, Akay OM, Uskudar Teke H, Andıc N, Gunduz E Abstract Chronic myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem/progenitor cell characterized by thrombohemorrhagic complications and a tendency to transform into acute leukemia. The pathogenesis of thrombosis in MPN is complex and results from a multifaceted interplay of clinical and disease-related factors. Rotational thromboelastometry (ROTEM) provides the complete and rapid information about all stages of the coagulation process. Here, we assess ROTEM parameters as a screening of coagulation profile in patients with MPNs. In particular, higher mean maximum clot firmness values were found in Essential thrombocythemia and Polycythemia vera patients when compared to healthy controls. Rotational thromboelastometry may be able to detect MPN patients who are susceptible to thrombotic and/or hemorrhagic complications. The predictive value of ROTEM for thrombosis remains to be established to classify subsets of patients at prominent risk who may benefit from prophylaxis with antithrombotic drugs. PMID: 32245332 [PubMed - as supplied by publisher]
Source: Platelets - Category: Hematology Tags: Platelets Source Type: research

Related Links:

CONCLUSION: As an easily accessible parameter, WBV might be a useful predictor of LVT formation within one year following acute anterior myocardial infarction. PMID: 32444531 [PubMed - as supplied by publisher]
Source: Biorheology - Category: Biochemistry Tags: Biorheology Source Type: research
Condition:   Leukemia, Lymphoblastic Intervention:   Behavioral: ETOILE therapeutic education Sponsor:   Assistance Publique - Hôpitaux de Paris Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Acute Lymphoblastic Leukemia, Pediatric;   Pediatric Cancer Interventions:   Behavioral: Active Music Engagement;   Behavioral: Audio Storybooks Sponsors:   Indiana University;   Children's Mercy Hospital Kansas City;   Ann&Robert H Lurie Children's Hospital of Chicago;   Riley Children's Health Indiana University Health Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 23 May 2020Source: Journal of Pediatric Surgery Case ReportsAuthor(s): Tri Hening Rahayatri, Harsya Dwindaru Gunardi, Rusdah Binti Muhammad Amin, Damayanti Sekarsari, Marini Stephanie, Sastiono Soedibyo, Seisuke Sakamoto, Mureo Kasahara
Source: Journal of Pediatric Surgery Case Reports - Category: Surgery Source Type: research
Publication date: Available online 23 May 2020Source: Journal of Vascular Surgery: Venous and Lymphatic DisordersAuthor(s): Nedaa Skeik, Aleem Mirza, Jesse Manunga
Source: Journal of Vascular Surgery: Venous and Lymphatic Disorders - Category: Surgery Source Type: research
Conclusions The discovery of JAK2V617F mutation in BCR-ABL1-negative MPNs by four different international cooperative groups in 2005 (2–5) led to significant insights on the pathogenesis of these disorders. In fact, this mutation results in a gain-of-function with activation of cytokine and growth factor receptors, and thus of the downstream JAK-STAT pathway (79, 95–98). The JAK2 point mutation in exon 12, present in a small percentage of patients with PV, is able to induce the MPN phenotype through the same pathogenic mechanism (6, 7). In 2006 the MPLW515L/K was reported in ET and PMF patients (44, 45) and d...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This article reviews existing data on cytoreduction, evaluating hydroxyurea, interferons, and ruxolitinib in ET and PV. This review evaluates whether evidence supports a more liberal strategy of cytoreduction for all patients with ET and PV. PMID: 30545998 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Conclusion. From the population viewpoint, ET and PV do not carry an increased excess mortality until late in the second follow-up decade or later. Nevertheless, appearance of a thrombotic event significantly increases the subsequent excess mortality.Figure 1DisclosuresHernandez Boluda: Incyte: Consultancy; Novartis: Consultancy. Ferrer Marin: Novartis: Consultancy, Research Funding; Incyte: Consultancy. Gómez-Casares: Bristol-Myers Squibb: Speakers Bureau; Incyte: Speakers Bureau; Novartis: Speakers Bureau. Cervantes: Celgene: Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria,...
Source: Blood - Category: Hematology Authors: Tags: 634. Myeloproliferative Syndromes: Clinical: Poster II Source Type: research
Polycythemia vera (PV) and essential thrombocythemia (ET) are chronic myeloproliferative neoplasms (MPN) associated with morbidity and mortality resulting from thrombosis or transformation to myelofibrosis and/or secondary acute leukemia. The acquired somatic mutation JAK2V617Fhas been observed in 98% of PV patients, and around 50% of ET patients. Interferon is known to be an effective treatment for chronic MPNs, but unlike hydroxyurea (HU, Hydrea®), it has been shown to target the malignant clone by decreasing JAK2V617Fallelic burden, and in some patients restoring polyclonal hematopoiesis. (Liu et al, Blood. 2003;101...
Source: Blood - Category: Hematology Authors: Tags: 634. Myeloproliferative Syndromes: Clinical Source Type: research
Authors: Vannucchi AM, Guglielmelli P Abstract Polycythemia vera (PV) and essential thrombocythemia (ET) are chronic myeloproliferative neoplasms that are characterized by thrombohemorrhagic complications, symptom burden, and impaired survival mainly due to thrombosis, progression to myelofibrosis, and transformation to acute leukemia. In this manuscript, we will review the most recent changes in diagnostic criteria, the improvements in risk stratification, and the "state of the art" in the daily management of these disorders. The role of conventional therapies and novel agents, interferon α and the...
Source: Hematology ASH Education Program - Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research
More News: Acute Leukemia | Chronic Leukemia | Chronic Myeloproliferative Neoplasm | Hematology | Leukemia | Myeloproliferative Disorders | Thrombosis